We're talking about steroid-refractory aGvHD and the important parameter of time - an improved product that's been available in an EAP, potential investigators becoming familiar with it and the approval of Ruxolitinib based on Reach1 whose results were truly appalling.
May I ask why you insist on pushing the narrative that SI avoided doing a "proper" when you've admitted to me you don't know whether or not KOL Dr. Susan Prockop was asked if she'd run one?
Taken up the entitlement?, page-409
-
- There are more pages in this discussion • 136 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
-0.075(5.12%) |
Mkt cap ! $1.587B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.46 | $1.37 | $9.337M | 6.672M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 80200 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 28642 | 2 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |